News & Media
Newsroom
European Medicines Agency Accepts Arvelle Therapeutics’ Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults
3.26.2020
Full Release
SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)
3.10.2020
Full Release
SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting
12.6.2019
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate brochure
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
To view the Hope, Hesitancy, and Hard Truths survey report, please click here.
Please see report infographic below
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 12 compounds under clinical development